Compound News and Research

RSS

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.

6 Dec 2012

Scientists identify key molecular pathway that leads to depression

Scientists have identified the key molecular pathway leading to depression, revealing potential new targets for drug discovery, according to research led by King's College London's Institute of Psychiatry. The study, published today in Neuropsychopharmacology, reveals for the first time that the 'Hedgehog pathway' regulates how stress hormones, usually elevated during depression, reduce the number of brain cells.

6 Dec 2012

Fexinidazole enters Phase II/III clinical study to treat sleeping sickness

A new oral-only treatment for sleeping sickness has entered Phase II/III clinical study in patients with late-stage sleeping sickness in the Democratic Republic of the Congo (DRC) and soon in Central African Republic (CAR).

6 Dec 2012

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Pfizer Inc. today announced randomized Phase 2 data that showed PD-0332991 (PD-991) in combination with letrozole significantly extended progression free survival (PFS) compared with letrozole alone in post-menopausal patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

6 Dec 2012

New technology allows noninvasive SpHb assessments for children undergoing brain surgery

For children undergoing brain surgery, a new technology allows noninvasive, continuous monitoring of blood hemoglobin levels, according to a study in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

6 Dec 2012

Rice bran offers promising cancer prevention properties

A recent University of Colorado Cancer Center review in the journal Advances in Nutrition shows that rice bran offers promising cancer prevention properties. Meanwhile, an ongoing clinical trial is testing the effectiveness of rice bran in preventing the recurrence of colon cancer.

6 Dec 2012

psi-GSH prevents neurodegeneration associated with Alzheimer's in mouse model

Researchers at the University of Minnesota's Center for Drug Design have developed a synthetic compound that, in a mouse model, successfully prevents the neurodegeneration associated with Alzheimer's disease.

4 Dec 2012

Merck commences MK-8931 Phase II/III trial in Alzheimer's

Merck, known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease.

3 Dec 2012

Scientists demonstrate how glowing fish can help screen drugs that control metabolic disorders

A tiny, translucent zebrafish that glows green when its liver makes glucose has helped an international team of researchers identify a compound that regulates whole-body metabolism and appears to protect obese mice from signs of metabolic disorders.

2 Dec 2012

Study shows how anaplasma phagocytophilum subverts natural processes

Bacteria that cause the tick-borne disease anaplasmosis in humans create their own food supply by hijacking a process in host cells that normally should help kill the pathogenic bugs, scientists have found.

30 Nov 2012

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

Boehringer Ingelheim today announced that new data evaluating volasertib, an investigational polo-like kinase (Plk) inhibitor, will be presented at the 54th American Society of Hematology (ASH) annual meeting taking place December 8-11 in Atlanta, Ga.

30 Nov 2012

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

DARA BioSciences, Inc., a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for KRN5500, a compound in development to treat a painful form of chronic chemotherapy-induced peripheral neuropathy (CCIPN).

30 Nov 2012

Novel SIRT2 inhibitor protects against neuronal damage in animal models of Huntington's

Treatment with a novel agent that inhibits the activity of SIRT2, an enzyme that regulates many important cellular functions, reduced neurological damage, slowed the loss of motor function and extended survival in two animal models of Huntington's disease.

30 Nov 2012

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).

30 Nov 2012

LP-211 compound shows promise against Fragile X syndrome

A potential new therapeutic strategy for treating Fragile X syndrome is detailed in a new report appearing in the current issue of Biological Psychiatry, from researchers led by Dr. Lucia Ciranna at University of Catania in Italy.

29 Nov 2012

New antifungal drugs could be developed based on substance bacteria use to decompose mushrooms

Soft rot diseases cause a great deal of damage in agriculture, and turn fruits, vegetables, and mushrooms to mush. By using imaging mass spectrometry together with genetic and bioinformatic techniques (genome mining), German researchers have now discovered the substance the bacteria use to decompose mushrooms.

29 Nov 2012

Bayer completes recruitment of first cohort for BAY 86-6150 Phase II/III study in hemophilia

Bayer's BAY 86-6150 is being investigated in a Phase II/III study called TRUST (TReatment with Unique recombinant rFVIIa STudy), and the recruitment of the first cohort is now complete.

28 Nov 2012

High CT utilization could increase risk of breast cancer for certain women

Researchers reviewing the records of approximately 250,000 women enrolled in an integrated healthcare delivery system found that increased CT utilization between 2000 and 2010 could result in an increase in the risk of breast cancer for certain women, including younger patients and those who received repeat exams.

27 Nov 2012

California researchers develop new strategy to find novel antibiotics for bacterial infections

Researchers at the University of California, Santa Cruz, have developed a new strategy for finding novel antibiotic compounds, using a diagnostic panel of bacterial strains for screening chemical extracts from natural sources.

27 Nov 2012

New recommendations on screening mammography may lead to missed cancers

Researchers assessing the impact of revised guidelines for screening mammography issued by the U.S. Preventive Services Task Force (USPSTF) found evidence that the new recommendations may lead to missed cancers and a decline in screening, according to two studies presented today at the annual meeting of the Radiological Society of North America (RSNA).

27 Nov 2012

Compound News and Research

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Scientists identify key molecular pathway that leads to depression

Fexinidazole enters Phase II/III clinical study to treat sleeping sickness

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

New technology allows noninvasive SpHb assessments for children undergoing brain surgery

Rice bran offers promising cancer prevention properties

psi-GSH prevents neurodegeneration associated with Alzheimer's in mouse model

Merck commences MK-8931 Phase II/III trial in Alzheimer's

Scientists demonstrate how glowing fish can help screen drugs that control metabolic disorders

Study shows how anaplasma phagocytophilum subverts natural processes

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

Novel SIRT2 inhibitor protects against neuronal damage in animal models of Huntington's

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

LP-211 compound shows promise against Fragile X syndrome

New antifungal drugs could be developed based on substance bacteria use to decompose mushrooms

Bayer completes recruitment of first cohort for BAY 86-6150 Phase II/III study in hemophilia

High CT utilization could increase risk of breast cancer for certain women

California researchers develop new strategy to find novel antibiotics for bacterial infections

New recommendations on screening mammography may lead to missed cancers

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News